Immunotherapy Use in Advanced Solid Tumors

EP. 1: The Immune System and Cancer Pathogenesis

July 6th 2016

EP. 2: Immunotherapy Modalities: Checkpoint Inhibitors and Vaccines

July 6th 2016

EP. 3: Adoptive Cell Therapy and Antibodies

July 6th 2016

EP. 4: PD-1 Inhibitor Use in Advanced Lung Cancer

July 6th 2016

EP. 5: PD-1 Inhibitor Use in Kidney and Bladder Cancers

July 6th 2016

EP. 6: PD-1 Inhibitor Use in Melanoma

July 6th 2016

EP. 7: The FDA Approval of Atezolizumab in Bladder Cancer

July 6th 2016

EP. 8: Combined Targeting Against VEGF and PD-1 in Bladder Cancer

July 6th 2016

EP. 9: The Emergence of PD-L1 Inhibitors

July 6th 2016

EP. 10: Immunotherapy in Novel Settings

July 6th 2016

EP. 11: Optimal Duration of Immunotherapy

July 6th 2016

EP. 12: Managing Immunotherapy-Related Toxicity

July 6th 2016

EP. 13: Oncolytic Viruses: Melanoma and Bladder Cancer

July 6th 2016

EP. 14: The Next Wave in Checkpoint Inhibition

July 6th 2016

EP. 15: Final Thoughts on Immunotherapy

July 6th 2016